MX2024001266A - 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer. - Google Patents

1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer.

Info

Publication number
MX2024001266A
MX2024001266A MX2024001266A MX2024001266A MX2024001266A MX 2024001266 A MX2024001266 A MX 2024001266A MX 2024001266 A MX2024001266 A MX 2024001266A MX 2024001266 A MX2024001266 A MX 2024001266A MX 2024001266 A MX2024001266 A MX 2024001266A
Authority
MX
Mexico
Prior art keywords
phenyl
gedatolisib
period
cancer
treatment
Prior art date
Application number
MX2024001266A
Other languages
English (en)
Inventor
Brian Francis Sullivan
Lance Gavin Laing
Original Assignee
Celcuity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celcuity Inc filed Critical Celcuity Inc
Publication of MX2024001266A publication Critical patent/MX2024001266A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos para tratar el cáncer en un sujeto humano; el método incluye seleccionar un sujeto que necesita tratamiento de cáncer; administrar al sujeto una cantidad terapéuticamente eficaz de gedatolisib al menos una vez a la semana durante un período de tres semanas; suspender la administración de gedatolisib durante un período de una semana; y reanudar la administración de gedatolisib al menos una vez a la semana después del período de interrupción; la administración durante al menos un período de tres semanas y la administración descontinuada durante al menos un período de una semana constituye un ciclo, donde el ciclo se repite durante al menos dos ciclos.
MX2024001266A 2021-07-26 2022-07-25 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer. MX2024001266A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225707P 2021-07-26 2021-07-26
US202163285327P 2021-12-02 2021-12-02
PCT/US2022/038188 WO2023009438A1 (en) 2021-07-26 2022-07-25 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2024001266A true MX2024001266A (es) 2024-04-16

Family

ID=82932627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001266A MX2024001266A (es) 2021-07-26 2022-07-25 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer.

Country Status (11)

Country Link
US (1) US20230022525A1 (es)
EP (1) EP4376848A1 (es)
JP (1) JP2024529430A (es)
KR (1) KR20240040768A (es)
AU (1) AU2022320615A1 (es)
CA (1) CA3227191A1 (es)
CL (1) CL2024000208A1 (es)
IL (1) IL310243A (es)
MX (1) MX2024001266A (es)
TW (1) TW202320795A (es)
WO (1) WO2023009438A1 (es)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
CA2594425A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
NZ588526A (en) 2008-05-23 2012-08-31 Wyeth Llc Triazine compounds as pi3 kinase and mtor inhibitors
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
SG189525A1 (en) 2010-10-25 2013-05-31 G1 Therapeutics Inc Cdk inhibitors
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
RU2015152171A (ru) 2013-06-19 2017-07-25 Серагон Фармасьютикалз, Инк. Азетидиновые модуляторы эстрогеновых рецепторов и их применения
TWI693937B (zh) 2014-03-14 2020-05-21 美商輝瑞大藥廠 包含治療劑之治療性奈米顆粒及其製造及使用方法
KR102016822B1 (ko) 2014-12-17 2019-08-30 화이자 인코포레이티드 정맥내 투여용 pi3k/mtor-억제제의 제형
EP3672571B1 (en) 2017-08-25 2021-10-06 Pfizer Inc. Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
WO2019234632A1 (en) 2018-06-07 2019-12-12 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
TW202027736A (zh) * 2018-10-08 2020-08-01 瑞士商赫孚孟拉羅股份公司 用PI3Kα抑制劑及二甲雙胍治療癌症之方法

Also Published As

Publication number Publication date
CA3227191A1 (en) 2023-02-02
EP4376848A1 (en) 2024-06-05
WO2023009438A1 (en) 2023-02-02
US20230022525A1 (en) 2023-01-26
TW202320795A (zh) 2023-06-01
IL310243A (en) 2024-03-01
CL2024000208A1 (es) 2024-07-19
JP2024529430A (ja) 2024-08-06
KR20240040768A (ko) 2024-03-28
AU2022320615A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
MX2023001468A (es) Tratamiento de cancer de prostata.
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
RU2001128504A (ru) Композиции для стимулирования роста
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
Almeida et al. Pilocarpine used to treat xerostomia in patients submitted to radioactive iodine therapy: a pilot study
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
MX2023010728A (es) Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2023013403A (es) Composicion farmaceutica para prevenir o tratar la fibrosis.
MX2023010657A (es) Inhibidores de los retrotransposones largos intercalados del elemento 1 (line-1) para tratar enfermedades del sistema nervioso central (snc) y sistemicas.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
MX2024001266A (es) 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer.
MX2023007420A (es) Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
WO2023019095A3 (en) Momelotinib combination therapy
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2023003583A (es) Forma cristalina del compuesto de piridinilfenilo y metodo de preparacion del mismo.
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
MX2024002566A (es) Regimen de dosificacion para un inhibidor de tead.
IL182462A0 (en) Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone